跳至主要内容
临床试验/DRKS00025852
DRKS00025852已完成不适用

Survival analysis of Acid Sphingomyelinase deficiency (ASMD) among German patients during childhood to adulthood: a retrospective chart review study - SURGE

Sanofi Genzyme0 个研究点目标入组 33 人开始时间: 2021年7月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • I 01.Pediatric, adolescent and adult ASMD (surviving and deceased) patients with retrievable information from German hospital medical records between January 1st 1990 and July 31st 2021.
  • I 02.A first date of evidence of ASMD defined as either first symptom onset or a diagnosis of ASMD Type B or A/B, whichever comes first. This first date of evidence of ASMD to be defined as the index date.
  • I 03.Patient and/or patient’s parent/legal guardian must provide informed assent/consent.

排除标准

  • E 01. Patients with no retrievable information from the medical record
  • E 02. Patients with ASMD type A

研究者

相似试验

Survival analysis of Acid Sphingomyelinase... | 临床试验